Impaired executive functioning in children of women with epilepsy

• Published in: Epilepsy & behavior Vol. 156; p. 109864
• Main Authors: Adriaenssen, Daniel Johannessen, Huuse Farmen, Anette, Glenne Øie, Merete, Winther Skogli, Erik
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2024
• Subjects: Adolescent; Adult; Anti-Seizure Medication; Anticonvulsants - adverse effects; Anticonvulsants - therapeutic use; BRIEF; Child; Child of Impaired Parents - psychology; Children; Epilepsy; Epilepsy - drug therapy; Epilepsy - psychology; Executive Function - physiology; Executive Functions; Female; Humans; Male; Mothers - psychology; Neuropsychological Tests; Pregnancy; Prenatal Exposure Delayed Effects; BRIEF; Children; Anti-Seizure Medication; Epilepsy; Executive Functions
• ISSN: 1525-5050; 1525-5069; 1525-5069
• DOI: 10.1016/j.yebeh.2024.109864

•This study reveals increased executive function (EF) problems in children of mothers with epilepsy, irrespective of anti-seizure medications (ASM) exposure, compared to typically developing children.•We found no significant difference in EF problems between children of mothers with epilepsy exposed to ASM and those unexposed to ASM.•Findings emphasize the need for ongoing monitoring of EF and research into factors beyond ASM affecting EF development in children of mothers with epilepsy. While neurodevelopmental symptoms are often seen in children of mothers with epilepsy, research specifically addressing executive function (EF) in this population is limited. This study aims to investigate EF in children of mothers with epilepsy, both with and without fetal exposure to anti-seizure medications, compared to typically developing children whose mothers do not have epilepsy. We evaluated EF in children aged 8 to 17 years born to mothers with clinically validated diagnoses of epilepsy, using the Behavior Rating Inventory of Executive Function completed by the mothers. The results were then compared to a typically developing control group at the same age living in the same geographic area. The results showed significantly higher levels of EF problems in children of mothers with epilepsy who were exposed (p = 0.005, d = 0.63), and unexposed (p = 0.001, d = 0.74) to anti-seizure medications during pregnancy, compared to typically developing children. There was no significant difference in EF problems between the exposed and unexposed groups. These findings remained statistically significant after adjusting for mothers’ education levels, and when excluding participants exposed to valproate during pregnancy. This study highlights the increased risk of EF problems in children of mothers with epilepsy, independent of exposure to anti-seizure medications. Findings underscore the importance of continuous monitoring of EF in these children and highlights the need for further research into the diverse factors affecting EF development in this group.